Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults
NCT04513899 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2024-03-01
Summary
This randomized controlled trial (RCT) will test the efficacy of a Community Health Worker/Registered Nurse (CHW-RN) HCV intervention for homeless individuals, many who are also drug users. The intervention will be designed during Phase I of the proposal using an iterative process between a Community Advisory Board (CAB) and focus groups. The CHW/RN intervention will occur over a 2 or 3 month (8-12 weeks) period depending on the Direct-Acting Antiviral (DAA) prescribed. Homeless adults assigned to the CHW/RN HCV treatment group will receive culturally-sensitive education, case management, and daily DOT delivery of DAA by an RN-guided CHW. The CHW will run a brief (20 min) weekly 1:1 education and 20 min case management session over the 8 or 12 weeks and will deliver all components of the program (which will be developed and refined during Phase I). The CHW-RN HCV intervention will be compared to a clinic-based standard of care group (cbSOC). Primary outcomes are the completion of the Direct-Acting Agent (DAA) treatment (month 2 or 3) and SVR12 Cure (month 5 or 6). Secondary outcomes are improved mental health status, decrease in substance use, and improved access to health care, and shelter stability at month 5 or 6.
Conditions
- Hepatitis C Virus (HCV) Infection
Interventions
- BEHAVIORAL
-
Community health worker (CHW)/ registered nurse (RN) [CHW/RN]
A team of 2-3 CHWs and a research RN will deliver all components of the program including daily DOT delivery of Direct Acting Antiviral (DAA) and assess HCV side effects all under the guidance of their RN. Recruitment will be continuous: each CHW may be assigned up to 7-8 participants every 2-3 months until the target sample size (n=54 for the intervention group) is achieved. After the first dose of the DAA, the CHW will run a brief weekly 1:1 education and case management session over the 8 or 12 weeks (total 20 minutes). The CHW/RN team will assist the participant in picking up the monthly medication and storing the medication in a secure, locked cabinet at the research office. The CHW will rigorously track participants who have missed a dose, and will also be involved in facilitating medical, mental health, substance use, social service, legal appointments for participants, housing referrals, and accompany the participants to the appointments.
- BEHAVIORAL
-
Clinic-based Standard of Care (cbSOC) Program (control group)
This program will be delivered by a clinic-based MD or clinic-based NP at the clinic site. Evaluation Staff (ES) will be hired and trained to do the interviewing/survey administration and follow-ups at the clinic-based site. The clinic NP will conduct, per usual care at the study clinics, the education and monitoring of these participants who will interact with the clinic-based-MD and/or NP monthly over the 8 or 12-week program. Usual care will include: 1) HCV pre-treatment education; 2) two month supply of DAA; 3) monitoring adverse events; and 4) responding to questions on HCV. Referral to drug/alcohol and housing programs will be provided over the standard of care. The cbSOC participants will not receive the community delivery of the DAA, or case management, or accompaniment to needed services. The cbSOC Program will receive the medication on a monthly basis from the clinic MD or NP.
Sponsors & Collaborators
-
University of California, Los Angeles
collaborator OTHER -
National Institute on Minority Health and Health Disparities (NIMHD)
collaborator NIH -
University of California, Irvine
lead OTHER
Principal Investigators
-
ADELINE M NYAMATHI, PhD · University of California, Irvine
-
Lillian Gelberg, MD · University of California, Los Angeles
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-10-05
- Primary Completion
- 2022-07-20
- Completion
- 2022-07-20
Countries
- United States
Study Locations
More Related Trials
-
Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.
NCT02641158 ·Status: COMPLETED ·Phase: NA
-
An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
NCT00722423 ·Status: COMPLETED ·Phase: NA
-
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
NCT03413696 ·Status: COMPLETED
-
Screening, Treatment, and Eradication of Hep C
NCT05071261 ·Status: NOT_YET_RECRUITING
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
NCT06179498 ·Status: RECRUITING ·Phase: NA
-
Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
NCT03214679 ·Status: COMPLETED ·Phase: NA
-
Hepatitis C Self-Management
NCT00328042 ·Status: COMPLETED ·Phase: NA
-
Motivational Interviewing for HCV Elimination
NCT03804814 ·Status: TERMINATED ·Phase: NA
-
Hepatitis C Treatment in Underserved Populations
NCT01717560 ·Status: UNKNOWN ·Phase: NA
-
Study to Reduce Intravenous Exposures (STRIVE)
NCT00391482 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Trial to Reduce Hepatitis C Among Injection Drug Users - 1
NCT00218192 ·Status: COMPLETED ·Phase: PHASE3
-
A Novel Hepatitis c micrOelimination Program in Non imprisonEd SenTenced With Alternative Measures
NCT03932396 ·Status: UNKNOWN
-
Conquering Hepatitis C Via Micro-Elimination in Southwest Virginia
NCT03876470 ·Status: UNKNOWN
-
Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs
NCT02609893 ·Status: COMPLETED ·Phase: PHASE4
-
Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection
NCT02707991 ·Status: COMPLETED ·Phase: NA
-
Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals
NCT02933970 ·Status: COMPLETED ·Phase: NA
-
Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients
NCT03057236 ·Status: COMPLETED ·Phase: NA
-
Antiviral Pharmacology and Adherence in Drug Users
NCT02573376 ·Status: COMPLETED ·Phase: NA
-
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
NCT02294136 ·Status: COMPLETED ·Phase: NA
-
Patient-Centered Models of HCV Care for People Who Inject Drugs
NCT02824640 ·Status: COMPLETED ·Phase: NA
-
Hepatitis C Treatment in Idaho County Jails
NCT06533319 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs
NCT03897608 ·Status: UNKNOWN
-
Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
NCT00674492 ·Status: COMPLETED
-
A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers
NCT04366973 ·Status: COMPLETED
-
HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment
NCT03524794 ·Status: UNKNOWN